The specialist drug development Company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases today reported half yearly results for the six months to December 2020. Against a backdrop of modest losses, the period was one of significant progress for Sareum’s two selective TYK2/JAK1 programmes, namely SDC1801, targeting autoimmune diseases, and SDC-1802, targeting cancer. Today’s release reveals that for SDC-1801 pre-clinical studies have enabl ....
